Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07273396

PHASE1/PHASE2

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

Sponsor: Seoul National University Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian cancer and peritoneal carcinomatosis.

Official title: A Phase 1/2a Study to Evaluate the Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer With Peritoneal Metastasis (PIPAC-OVPAC 1/2a)

Key Details

Gender

FEMALE

Age Range

19 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-01-01

Completion Date

2030-08-31

Last Updated

2025-12-09

Healthy Volunteers

Conditions

Ovarian Neoplasms Peritoneal Neoplasms

Interventions

DRUG

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel

All patients enrolled in this study receive PIPAC using paclitaxel under 12 mmHg at 6 weeks intervals (up to 9 cycles) 1. Phase 1 Design 1. Dose Escalation: Standard 3+3 design across 5 paclitaxel cohorts (20 → 40 → 67 → 100 → 140 mg/m²) using modified Fibonacci increments (100%, 67%, 50%, 40%). 2. Maximum tolerated dose(MTD) Determination * If ≥2/6 patients in cohort χ experience dose limiting toxicities(DLTs; Grade ≥3 toxicity per CTCAE v5.0, excluding manageable pain) and ≤1/6 in cohort χ-1, MTD = χ-1. * If no DLTs at 140 mg/m², Phase 1 concludes. 3. Dose Reduction * DLTs in 20 mg/m² trigger de-escalation to 10 mg/m². * If ≤1/6 DLTs in 10 mg/m² → RP2D; ≥2/6 DLTs → trial termination. 2. Phase 2 Design : Evaluates efficacy/safety of PIPAC at the RP2D in 23 patients, adjusting for 5-17% laparoscopic access failure.

Inclusion Criteria: 1. Age: Women aged 19-85 years. 2. Diagnosis: Histologically confirmed ovarian, fallopian tube, or peritoneal cancer. 3. Platinum Status: * Refractory: Disease progression during platinum-based chemotherapy. * Resistant: Progression within 6 months (24 weeks) post-platinum therapy. 4. Prior Therapies: ≥2 prior intravenous chemotherapies (may include paclitaxel). 5. Treatment Options: Unresponsive to/ineligible for standard therapies (e.g., intolerance, hypersensitivity) and ineligible for surgical resection. 6. Measurable Disease: ≥1 measurable/evaluable peritoneal lesion per RECIST 1.1. 7. Metastasis: ≤1 asymptomatic distant metastasis (excluding retroperitoneal lymph nodes, pleural effusion, localized skin metastases). 8. Imaging Confirmation: Peritoneal carcinomatosis confirmed by PET-CT/CT. 9. Performance Status: ECOG 0-2. 10. Pregnancy/Contraception: * Non-pregnant/non-lactating. * Contraception: Effective methods (IUD, sterilization) for 6 months post-PIPAC (childbearing potential only). 11. Organ Function: * Bone Marrow: ANC \>1,500/mm³, platelets \>100,000/mm³, hemoglobin \>8.0 g/dL. * Liver: Bilirubin ≤1.5×ULN, AST/ALT ≤1.5×ULN. * Kidney: Creatinine ≤1.5×ULN, creatinine clearance \>60 mL/min. * Lungs: FVC/FEV1 ≥70% predicted. * Coagulation: INR ≤1.5, aPTT ≤1.5×ULN. 12. Consent: Signed informed consent. Exclusion Criteria: 1. ≥2 distant metastases (excluding retroperitoneal lymph nodes, pleural effusion, and localized skin metastases). 2. Contraindications to paclitaxel per approved domestic labeling. 3. Hypersensitivity history to paclitaxel or PIPAC devices. 4. Uncontrolled comorbidities per investigator judgment: * NYHA Class ≥II heart failure * Clinically significant cardiovascular disease (e.g., arrhythmia, myocardial infarction) * Immunosuppressive conditions (AIDS, autoimmune diseases, immunosuppressive therapy) * Active HBV/HCV infection * Uncontrolled hypertension (systolic \>160 mmHg or diastolic \>100 mmHg) * Uncontrolled diabetes (HbA1c \>8%) * Radiographic/clinical bowel obstruction. 5. IV chemotherapy within 4 weeks prior to Cycle 1 PIPAC. 6. Life expectancy \<3 months. 7. Prior PIPAC therapy. 8. Medically unfit for general anesthesia or laparoscopic surgery. 9. Refusal of contraception: \- Medically acceptable methods: * Intrauterine device (failure rate \<1%) * Surgical sterilization (tubal ligation, hysterectomy, vasectomy; failure rate \<0.5%). 10. Participation in another clinical trial within 1 month of screening. 11. Other exclusionary factors per investigator discretion.